Virginia Retirement Systems ET AL grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 17.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,076,032 shares of the company’s stock after purchasing an additional 157,300 shares during the period. Johnson & Johnson comprises about 1.7% of Virginia Retirement Systems ET AL’s holdings, making the stock its 4th largest holding. Virginia Retirement Systems ET AL’s holdings in Johnson & Johnson were worth $149,870,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of JNJ. Thoroughbred Financial Services LLC lifted its stake in Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Johnson & Johnson by 14.2% in the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after acquiring an additional 1,079,751 shares during the last quarter. Mn Services Vermogensbeheer B.V. lifted its stake in shares of Johnson & Johnson by 152.1% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock valued at $122,372,000 after acquiring an additional 654,085 shares during the last quarter. Royal London Asset Management Ltd. lifted its stake in shares of Johnson & Johnson by 53.2% in the 4th quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock valued at $199,471,000 after acquiring an additional 648,775 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Johnson & Johnson by 2,178.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock valued at $83,759,000 after acquiring an additional 620,558 shares during the last quarter. 67.35% of the stock is owned by hedge funds and other institutional investors.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, June 11th. The shares were bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at $419,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is owned by insiders.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the previous year, the business earned $2.10 EPS. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.85%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
A number of equities research analysts have recently weighed in on the company. Barclays assumed coverage on Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. BMO Capital Markets boosted their target price on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Morgan Stanley boosted their price target on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a report on Wednesday, April 17th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $148.56.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.